

# Curdin Conrad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615364/publications.pdf>

Version: 2024-02-01

80  
papers

7,917  
citations

109137

35  
h-index

66788

78  
g-index

86  
all docs

86  
docs citations

86  
times ranked

10091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1652-1660.	1.1	20
2	Papillon-Delefevre syndrome treated by acitretin: case report and cytokine profile. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	4
3	Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 675-683.	0.6	5
4	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	1.4	6
5	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	1.3	10
6	The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. <i>Nature</i> , 2022, 603, 145-151.	13.7	272
7	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
8	TYK-ing all the boxes in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1936-1939.	1.5	3
9	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1578-1583.	1.3	11
10	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.4	32
11	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 233-241.	1.4	4
12	Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021—a two-round Delphi survey among international experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1467-1476.	1.3	14
13	Biomarkers of disease progression in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 481-493.	1.4	22
14	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. <i>British Journal of Dermatology</i> , 2022, 187, 494-506.	1.4	14
15	Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the <scp>SERENA</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1796-1804.	1.3	6
16	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 123-134.	1.3	25
17	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1650.	1.8	11
18	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. <i>Antibodies</i> , 2021, 10, 12.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	3.3	65
20	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.4	21
21	Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. <i>British Journal of Dermatology</i> , 2021, 185, 865-867.	1.4	5
22	Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. <i>Dermatology</i> , 2021, 237, 166-178.	0.9	17
23	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 476-483.	1.1	23
24	The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin. <i>Nature Immunology</i> , 2020, 21, 1034-1045.	7.0	90
25	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5102.	1.8	26
26	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). <i>Dermatology and Therapy</i> , 2020, 10, 663-670.	1.4	28
27	Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 261-263.	0.6	3
28	Baricitinib-induced paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e391-e393.	1.3	6
29	Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2330-2338.	1.3	13
30	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2313-2318.	1.3	2
31	Human $\gamma\delta$ T cells are a subpopulation of PPAR $\gamma$ T <sub>H</sub> 2 cells. <i>Science Immunology</i> , 2019, 4, .	5.6	75
32	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	0.6	39
33	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1732-1742.e17.	0.3	42
34	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	2.5	40
35	Psoriasis: from Pathogenesis to Targeted Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 102-113.	2.9	151
36	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. <i>Nature Communications</i> , 2018, 9, 25.	5.8	194

#	ARTICLE	IF	CITATIONS
37	Diversification of human plasmacytoid predendritic cells in response to a single stimulus. <i>Nature Immunology</i> , 2018, 19, 63-75.	7.0	106
38	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018, 25, 3564-3572.e4.	2.9	49
39	Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. <i>Frontiers in Immunology</i> , 2018, 9, 2746.	2.2	96
40	Xenotransplantation Model of Psoriasis. <i>Methods in Molecular Biology</i> , 2017, 1559, 83-90.	0.4	7
41	Interleukin 23/Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. <i>JAMA Dermatology</i> , 2017, 153, 304.	2.0	111
42	Infections Associated with Immunobiologics. , 2017, , 796-804.e2.		0
43	Psoriasis, Cutaneous Lupus Erythematosus and Immunobiology of the Skin. , 2016, , 192-203.		0
44	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. <i>Dermatology</i> , 2016, 232, 640-647.	0.9	32
45	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. <i>Dermatology</i> , 2016, 232, 655-663.	0.9	18
46	PASS Syndrome: An IL-1-Driven Autoinflammatory Disease. <i>Dermatology</i> , 2016, 232, 254-258.	0.9	51
47	Targeting CD8+ T cells prevents psoriasis development. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 274-276.e6.	1.5	125
48	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	0.9	39
49	The Dermatologists' Role in Managing Psoriatic Arthritis: Results of a Swiss Delphi Exercise Intended to Improve Collaboration with Rheumatologists. <i>Dermatology</i> , 2015, 230, 75-81.	0.9	13
50	TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. <i>Nature Immunology</i> , 2015, 16, 970-979.	7.0	182
51	Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. <i>European Journal of Immunology</i> , 2015, 45, 203-213.	1.6	129
52	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	5.8	427
53	Purpura of the Face and Neck: An Atypical Clinical Presentation Revealing a Hepatosplenic T Cell Lymphoma. <i>Case Reports in Dermatology</i> , 2014, 6, 37-42.	0.3	2
54	Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment. <i>OncolImmunology</i> , 2013, 2, e23887.	2.1	17

#	ARTICLE	IF	CITATIONS
55	Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. <i>Psoriasis: Targets and Therapy</i> , 2013, , 1.	1.2	5
56	Anti-TNF Therapy in the Treatment of Psoriasis in a Patient with Acute-on-Chronic Pancreatitis. <i>Dermatology</i> , 2013, 227, 193-196.	0.9	9
57	Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells. <i>Cancer Research</i> , 2012, 72, 5240-5249.	0.4	267
58	Type I IFNs at the Interface between Cutaneous Immunity and Epidermal Remodeling. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1759-1762.	0.3	18
59	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNAâ€“Peptide Complexes in Systemic Lupus Erythematosus. <i>Science Translational Medicine</i> , 2011, 3, 73ra19.	5.8	1,080
60	Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. <i>Journal of Immunology</i> , 2010, 185, 5688-5691.	0.4	207
61	Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. <i>Journal of Experimental Medicine</i> , 2010, 207, 2921-2930.	4.2	292
62	Trauma as Triggering Factor for Development of Melanocytic Nevi. <i>Dermatology</i> , 2010, 220, 291-296.	0.9	18
63	Melanoma and innate immunity â€“ Active inflammation or just erroneous attraction?. <i>Seminars in Cancer Biology</i> , 2009, 19, 84-91.	4.3	35
64	Interplay between keratinocytes and immune cellsâ€“Recent insights into psoriasis pathogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 963-968.	1.2	92
65	Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. <i>Seminars in Immunology</i> , 2009, 21, 101-109.	2.7	56
66	The pathogenic role of tissue-resident immune cells in psoriasis. <i>Trends in Immunology</i> , 2007, 28, 51-57.	2.9	128
67	Î±1Î²1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. <i>Nature Medicine</i> , 2007, 13, 836-842.	15.2	241
68	Animal models of psoriasis and psoriatic arthritis: An update. <i>Current Rheumatology Reports</i> , 2006, 8, 342-347.	2.1	17
69	Current State and Perspectives of Dendritic Cell Vaccination in Cancer Immunotherapy. <i>Skin Pharmacology and Physiology</i> , 2006, 19, 124-131.	1.1	16
70	Dendritic-cell-based therapeutic vaccination against cancer. <i>Current Opinion in Immunology</i> , 2005, 17, 163-169.	2.4	182
71	Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.. <i>British Journal of Dermatology</i> , 2005, 152, 1211-1218.	1.4	46
72	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. <i>Nature Medicine</i> , 2005, 11, 138-145.	15.2	356

#	ARTICLE	IF	CITATIONS
73	Pyoderma gangrenosum. Pyoderma gangraenosum. JDDG - Journal of the German Society of Dermatology, 2005, 3, 334-342.	0.4	49
74	Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. Journal of the National Cancer Institute, 2005, 97, 1143-1153.	3.0	173
75	Plasmacytoid predendritic cells initiate psoriasis through interferon- $\hat{\pm}$ production. Journal of Experimental Medicine, 2005, 202, 135-143.	4.2	999
76	Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors. Archives of Dermatology, 2004, 140, 1490-5.	1.7	364
77	The IL-12 Family Member p40 Chain as a Master Switch and Novel Therapeutic Target in Psoriasis. Journal of Investigative Dermatology, 2004, 123, xiv-xv.	0.3	49
78	Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor- $\hat{\pm}$ . Journal of Experimental Medicine, 2004, 199, 731-736.	4.2	463
79	Mechanisms of psoriasis. Drug Discovery Today Disease Mechanisms, 2004, 1, 315-319.	0.8	16
80	Dendritic cell-based cancer therapy. Current Opinion in Molecular Therapeutics, 2003, 5, 405-12.	2.8	11